Preclinical studies in squamous cell carcinoma models have demonstrated that the application of volasertib during fractionated irradiation significantly reduced tumor growth compared to irradiation alone (Lund-Andersen et al., 2014), providing a strong rationale for combining PLK1 inhibition with radiotherapy to overcome radioresistance. The gene discussed is PLK1; the disease is neoplasm.